Lyra Therapeutics Inc. (NASDAQ: LYRA)
$0.31
-0.0037 ( -1.19% ) 296.0K
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Market Data
Open
$0.31
Previous close
$0.31
Volume
296.0K
Market cap
$18.67M
Day range
$0.31 - $0.32
52 week range
$0.25 - $6.79
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 63 | Aug 08, 2023 |
8-k | 8K-related | 14 | Aug 08, 2023 |
8-k | 8K-related | 13 | Jul 14, 2023 |
4/a | Other | 1 | Jul 12, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |